Monitoring of circulating CAR T cells [WEBINAR]

Explain the importance of monitoring circulating CAR T cells using flow cytometry to track therapy success, including expansion, persistence, differentiation, exhaustion, and activation analysis.

Detail the essential characteristics of reliable CAR detection reactions: consistent lot-to-lot performance, compatibility with different CAR constructs, sensitivity for small cell populations, specificity for true positives, accuracy across samples, and reproducibility.

Describe the antigen-based approach using target proteins (e.g., CD19) fused with biotin-labeled FC backbone, detected by fluorochrome-labeled biotin antibodies to amplify signal and increase sensitivity.

Describe the idiotype antibody approach where recombinant antibodies recognize the scFv region of specific CAR receptors, enabling narrow specificity and one-step staining protocols.

Compare multinibiotech CAR detection reagents against negative controls and competitor products to show superior specificity and significantly lower background staining on negative specimens.

Outline a clinical flow cytometry assay validation addressing sensitivity, precision, stability, accuracy versus PCR, and specificity for monitoring CAR T cells in pediatric lymphoblastic leukemia patients.

Present quantification data down to 0.01% CAR T cell fraction and precision measurements (intra-assay, inter-assay, inter-instrument) across high, intermediate, and low positive controls.

Evaluate accuracy by correlating 46 patient samples measured with both flow cytometry and real-time PCR, and assess sample stability over five consecutive measurement days.